Speciality: Gastroenterology
Description:
A warm welcome to all the medical professionals in this interesting session of Tofacitinib in the treatment of Ulcerative Colitis.. We have Prof. Anand N. Malaviya, Dr Indrajit Agrawal, and Dr Sanjiv Kapoor to lead the session.
Ulcerative colitis treatment usually involves either medication therapy or surgery. Different categories of medications can help in treating ulcerative colitis.
Tofacitinib inhibits the process of intracellular signaling from the receptor to the cellular nucleus and inhibits the inflammation process via inhibition of the Janus kinases, which eventually helps in controlling different inflammatory diseases.
Oral formulation of tofacitinib has been approved for the treatment of patients with moderate–severe ulcerative colitis as Tofacitinib and other JAK inhibitors address an unmet need in the armamentarium of IBD therapy.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
2.
More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.
3.
What Role Should Genomic Classifier Testing Play in Prostate Cancer?
4.
A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma
5.
Squeezing through tiny blood vessels may trigger melanoma cells to spread
1.
The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies
2.
Everything You Need to Know About Leiomyomas: A Comprehensive Guide
3.
The Importance of Corrected Calcium Levels in Managing Health Conditions
4.
How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies
5.
Cowden Syndrome and Cancer: Understanding the Risk Factors
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
3.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation